Skip to main content

Advertisement

SpringerLink
Log in

Plasma fibrin clot properties in atopic dermatitis: links between thrombosis and atopy

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Myocardial infarction and ischemic stroke are associated with formation of dense fibrin clots resistant to lysis. Although pro- and antithrombotic alterations have been reported in atopy, fibrin clot function has not been studied in atopic patients. The aim of the current study was to investigate fibrin clot properties in patients with atopic dermatitis (AD). Plasma fibrin clot permeability, turbidity and clot lysis were assessed in 130 consecutive AD patients, aged 29.7 ± 11 [±SD] years (mean SCORAD index, 32.4 ± 14.9), free of thrombotic events. A control group comprised 130 healthy controls matched for demographics. Patients with AD had lower clot permeability (7.12 ± 1.87 vs. 9.32 ± 0.86 × 10−9 cm2; P < 0.0001), increased fiber thickness (maximum clot absorbancy at 405 nm, 4.03 ± 0.54 vs. 3.47 ± 0.25), faster clot formation (the lag phase, 39.16 ± 4.61 vs. 43.05 ± 4.56 s), higher maximum D-dimer levels released from clots, reflecting increased clot mass (4.05 ± 0.57 vs. 3.47 ± 0.25 mg/l; P < 0.0001), lower rate of D-dimer release (0.073 ± 0.01 vs. 0.078 ± 0.01 mg/l/min; P < 0.0001), and prolonged fibrinolysis time (9.26 ± 1.47 vs. 7.81 ± 1.17 min; P < 0.0001) compared with controls. Concomitant asthma (n = 36; 27.7%) was related to a higher rate of D-dimer release from clots than the remainder (0.075 ± 0.01 vs. 0.072 ± 0.01 mg/l/min, respectively; P = 0.03). Altered plasma fibrin clot properties associated with reduced efficiency of fibrinolysis can be detected in AD patients, which might represent a novel mechanism that modulates a hemostatic balance in atopy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jung T, Stingl G (2008) Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights. J Allergy Clin Immunol 122:1074–1081

    Article  CAS  PubMed  Google Scholar 

  2. Ryan JJ, Kashyap M, Bailey D et al (2007) Mast cell homeostasis: a fundamental aspect of allergic disease. Crit Rev Immunol 27:15–32

    CAS  PubMed  Google Scholar 

  3. Kovanen PT (2007) Mast cells: multipotent local effector cells in atherothrombosis. Immunol Rev 217:105–122

    Article  CAS  PubMed  Google Scholar 

  4. Leskinen MJ, Heikkilä HM, Speer MY et al (2006) Mast cell chymase induces smooth muscle cell apoptosis by disrupting NF-kappaB-mediated survival signaling. Exp Cell Res 312:1289–1298

    Article  CAS  PubMed  Google Scholar 

  5. Kovanen PT (2007) Mast cells and degradation of pericellular and extracellular matrices: potential contributions to erosion, rupture and intraplaque haemorrhage of atherosclerotic plaques. Biochem Soc Trans 35:857–861

    Article  CAS  PubMed  Google Scholar 

  6. Tamagawa-Mineoka R, Katoh N, Kishimoto S (2009) Platelets play important roles in the late phase of the immediate hypersensitivity reaction. J Allergy Clin Immunol 123:581–587

    Article  CAS  PubMed  Google Scholar 

  7. Thomas VA, Wheeless CJ, Stack MS et al (1998) Human mast cell tryptase fibrinogenolysis: kinetics, anticoagulation mechanism, and cell adhesion disruption. Biochemistry 24:2291–2298

    Article  Google Scholar 

  8. Caughey GH (2006) Tryptase genetics and anaphylaxis. J Allergy Clin Immunol 117:1411–1414

    Article  CAS  PubMed  Google Scholar 

  9. Wojta J, Huber K, Valent P (2004) New aspects in thrombotic research: complement induced switch in mast cells from a profibrinolytic to a prothrombotic phenotype. Pathophysiol Haemost Thromb 33:438–441

    Article  Google Scholar 

  10. Wojta J, Kaun C, Zorn G et al (2002) C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood 100:517–523

    Article  CAS  PubMed  Google Scholar 

  11. Cho SH, Tam SW, Demissie-Sanders S et al (2000) Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma. J Immunol 165:3154–3161

    CAS  PubMed  Google Scholar 

  12. Hamuro T, Kido H, Asada Y et al (2007) Tissue factor pathway inhibitor is highly susceptible to chymase-mediated proteolysis. FEBS J 274:3065–3077

    Article  CAS  PubMed  Google Scholar 

  13. Scott EM, Ariëns RAS, Grant PJ (2004) Genetic and environmental determinants of fibrin structure and function. Relevance to clinical disease. Arterioscler Thromb Vasc Biol 24:1558–1566

    Article  CAS  PubMed  Google Scholar 

  14. Undas A, Szuldrzynski K, Stepien E et al (2007) Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 196:551–558

    Article  PubMed  Google Scholar 

  15. Fatah K, Hamsten A, Blombäck B, Blombäck M (1992) Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 68:130–135

    CAS  PubMed  Google Scholar 

  16. Collet JP, Allali Y, Lesty C et al (2006) Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 26:2567–2573

    Article  CAS  PubMed  Google Scholar 

  17. Ajjan RA, Standeven KF, Khanbhai M et al (2009) Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol 29:712–717

    Article  CAS  PubMed  Google Scholar 

  18. Undas A, Podolec P, Zawilska K et al (2009) Altered fibrin clot structure/function as a novel risk factor for cryptogenic ischemic stroke. Stroke 40:1499–1501

    Article  CAS  PubMed  Google Scholar 

  19. Undas A, Zawilska K, Ciesla-Dul M et al (2009) Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 114:4272–4278

    Article  CAS  PubMed  Google Scholar 

  20. Oranje AP, Glazenburg EJ, Wolkerstorfer A et al (2007) Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the tree-item severity score. Br J Dermatol 157:645–648

    Article  CAS  PubMed  Google Scholar 

  21. Veraldi S, De Micheli P, Schianchi R et al (2009) Treatment of pruritus in mild-to-moderate atopic dermatitis with topical non-steroidal agent. J Drugs Dermatol 8:537–539

    PubMed  Google Scholar 

  22. Mills JD, Ariëns RA, Mansfield MW, Grant PJ (2002) Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 106:1938–1942

    Article  CAS  PubMed  Google Scholar 

  23. Mekori YA, Galli SJ (1990) [125I] Fibrin deposition occurs at both early and late intervals of IgE-dependent or contact sensitivity reactions elicited in mouse skin. Mast cell-dependent augmentation of fibrin deposition at early intervals in combined IgE-dependent and contact sensitivity reactions. J Immunol 145:3719–3727

    CAS  PubMed  Google Scholar 

  24. Kawakami T, Kaminishi K, Soma Y et al (2006) Oral antihistamine therapy influences plasma tryptase levels in adult atopic dermatitis. J Dermatol Sci 43:127–134

    Article  CAS  PubMed  Google Scholar 

  25. Undas A, Celinska-Lowenhoff M, Lowenhoff T, Szczeklik A (2006) Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 4:1029–1036

    Article  CAS  PubMed  Google Scholar 

  26. Undas A, Topor-Madry R, Tracz W (2009) Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l. Pol Arch Med Wewn 119:354–359

    CAS  PubMed  Google Scholar 

  27. Weisel JW, Litvinov RI (2008) The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem 6:161–180

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Anetta Undas was supported by a grant of Jagiellonian University School of Medicine no. K/ZDS/000565.

Conflict of interest statement

All authors have no conflict of interest to disclose.

Author information

Authors and Affiliations

  1. Department of Dermatology, Jagiellonian University School of Medicine, Krakow, Poland

    Magdalena Nastałek & Anna Wojas-Pelc

  2. Institute of Cardiology, Jagiellonian University School of Medicine, 80 Pradnicka St, 31-202, Krakow, Poland

    Anetta Undas

Authors
  1. Magdalena Nastałek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Wojas-Pelc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anetta Undas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anetta Undas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nastałek, M., Wojas-Pelc, A. & Undas, A. Plasma fibrin clot properties in atopic dermatitis: links between thrombosis and atopy. J Thromb Thrombolysis 30, 121–126 (2010). https://doi.org/10.1007/s11239-010-0478-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-010-0478-0

Keywords

Search

Navigation